Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Gross Margin (2021 - 2024)

Goldenwell Biotech's Gross Margin history spans 4 years, with the latest figure at 53.8% for Q4 2024.

  • For Q4 2024, Gross Margin rose 2572.0% year-over-year to 53.8%; the TTM value through Sep 2025 reached 39503.16%, down 3953900.0%, while the annual FY2024 figure was 46.04%, 977.0% up from the prior year.
  • Gross Margin reached 53.8% in Q4 2024 per GWLL's latest filing, up from 50.36% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 53.8% in Q4 2024 to a low of 28.08% in Q4 2023.
  • Average Gross Margin over 4 years is 49.7%, with a median of 52.53% recorded in 2021.
  • Peak YoY movement for Gross Margin: crashed -402bps in 2023, then skyrocketed 2572bps in 2024.
  • A 4-year view of Gross Margin shows it stood at 52.54% in 2021, then rose by 0bps to 52.71% in 2022, then tumbled by -47bps to 28.08% in 2023, then skyrocketed by 92bps to 53.8% in 2024.
  • Per Business Quant, the three most recent readings for GWLL's Gross Margin are 53.8% (Q4 2024), 50.36% (Q2 2024), and 28.08% (Q4 2023).